Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: Comparison of the porcine and rat responses

Journal of Controlled Release

Volumn 195, Issue , 2014, Pages 2-10

  Dézsi, László ^a   Fülöp, Tamás ^a   Mészáros, Tamás ^a   Szénási, Gábor ^a,b   Urbanics, Rudolf ^c   Vázsonyi, Csenge ^a   Orfi, Erik ^a   Rosivall, László ^a,b   Nemes, Réka ^d   Kok, Robbert Jan ^d   Metselaar, Josbert M ^e   Storm, Gert ^d,e   Szebeni, János ^a,c,f  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c SeroScience Ltd   (Hungary)

^d UTRECHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF TWENTE   (Netherlands)

^f UNIVERSITY OF MISKOLC   (Hungary)

Author keywords

Adverse drug effects; Anaphylatoxins; Anaphylaxis; CARPA; Nanomedicines; Pseudoallergy

Indexed keywords

BLOOD PRESSURE; CHEMICAL ACTIVATION; LIPOSOMES; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES;

ANAPHYLATOXINS; ANAPHYLAXIS; CARPA; DRUG EFFECTS; NANOMEDICINES; PSEUDOALLERGY;

RATS;

AMPHOTERICIN B LIPID COMPLEX; CHOLESTEROL; COMPLEMENT COMPONENT C3; LIPOSOME; MACROGOL; PHOSPHOLIPID; THROMBOXANE B2; ZYMOSAN; LIPID; MACROGOL DERIVATIVE;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BOLUS INJECTION; COMPLEMENT ACTIVATION; COMPLEMENT ACTIVATION RELATED PSEUDOALLERGY; CONTROLLED STUDY; HEMODYNAMICS; HYPOTENSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LEUKOPENIA; LIPOSOMAL DELIVERY; MALE; NONHUMAN; PULMONARY HYPERTENSION; RAT; SPECIES COMPARISON; SURFACE CHARGE; SURFACE PROPERTY; SWINE; TACHYPHYLAXIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ANIMAL; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG HYPERSENSITIVITY; HEART RATE; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; PIG; SPECIES DIFFERENCE; WISTAR RAT;

ANIMALS; COMPLEMENT ACTIVATION; DRUG HYPERSENSITIVITY; HEART RATE; HUMANS; HYPOTENSION; LEUKOCYTE COUNT; LIPIDS; LIPOSOMES; MALE; PLATELET COUNT; POLYETHYLENE GLYCOLS; RATS, WISTAR; SPECIES SPECIFICITY; SURFACE PROPERTIES; SWINE; THROMBOXANE B2;

EID: 84908503105     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.08.009     Document Type: Article

References (41)

1. J. Szebeni, J.L. Fontana, N.M. Wassef, P.D. Mongan, D.S. Morse, D.E. Dobbins, G.L. Stahl, R. Bünger, and C.R. Alving Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody Circulation 99 1999 2302 2309
2. J. Szebeni Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity Toxicology 216 2005 106 121
3. S.M. Moghimi, and J. Szebeni Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties Prog. Lipid Res. 42 2003 463 478
4. A.J. Andersen, S.H. Hashemi1, T.L. Andresen, A.C. Hunter, and S.M. Moghimi Complement: alive and kicking nanomedicines J. Biomed. Nanotechnol. 5 2009 364 372
5. S.M. Moghimi, I. Hamad, T.L. Andresen, K. Jörgensen, and J. Szebeni Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production FASEB J. 20 2006 2591 2593
6. J. Szebeni, F. Muggia, G. Gabizon, and Y. Barenholz Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention Adv. Drug Deliv. Rev. 63 2011 1020 1030
7. J. Szebeni Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions Eur. J. Nanomed. 5 2012 33 53
8. J. Szebeni, and Y. Barenholz Complement activation, immunogenicity, and immune suppression as potential side effects of liposomes D. Peer, Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications 2012 Pan Stanford Publishing Pte. Ltd. Singapore 309 334
9. European Medicines Agency Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/07/WC500109479.pdf (EMA/CHMP/806058/(2011 July 21))
10. American National Standards Institute Association for the advancement of medical instrumentation and international organization for standardization, biological evaluation of medical devices - part 4: selection of tests for interaction with blood ANSI/AAMI/ISO 10993-4:2002/(R), 10 March 2009 2009
11. L. Dézsi, G. Szénási, R. Urbanics, L. Rosivall, and J. Szebeni Cardiopulmonary and hemodynamic changes in complement activation-related pseudoallergy Health 6 2013 1032 1038
12. J. Szebeni, R. Bunger, L. Baranyi, P. Bedocs, M. Toth, L. Rosivall, Y. Barenholz, and C.R. Alving Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles J. Liposome Res. 17 2007 107 117
13. J. Szebeni, B. Baranyi, S. Savay, M. Bodo, D.S. Morse, M. Basta, G.L. Stahl, R. Bunger, and C.R. Alving Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction Am. J. Physiol. 279 2000 H1319 H1328
14. J. Szebeni, L. Baranyi, S. Sávay, M. Bodó, J. Milosevits, C.R. Alving, and R. Bünger Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function Am. J. Physiol. 290 2006 H1050 H1058
15. J. Szebeni, P. Bedocs, D. Csukás, L. Rosivall, R. Bunger, and R. Urbanics A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines Adv. Drug Deliv. Rev. 64 2012 1706 1716
16. J. Szebeni, P. Bedocs, Z. Rozsnyay, Z. Weiszhár, R. Urbanics, L. Rosivall, R. Cohen, O. Garbuzenko, G. Báthori, M. Tóth, R. Bünger, and Y. Barenholz Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome Nanomedicine: NBM 8 2012 176 184
17. J. Szebeni, P. Bedõcs, R. Urbanics, R. Bunger, L. Rosivall, M. Tóth, and Y. Barenholz Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model J. Control. Release 160 2012 382 387
18. R. Rabinovici, W.T. Phillips, G. Feuerstein, and A.S. Rudolph Encapsulation of Hemoglobin in Liposomes, in Red Blood Cell Substitutes: Fundamental Principles and Clinical Applications R. Rabinovici, G. Feuerstein, A.S. Rudolph, 1998 Marcel Dekker New York 263 287
19. R. Rabinovici, A.S. Rudolph, and G. Feuerstein Characterization of hemodynamic, hematologic and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, freely moving rat Circ. Shock. 29 1989 115 132
20. R. Rabinovici, A.S. Rudolph, F.S. Ligler, E.F. Smith III, and G. Feuerstein Biological responses to exchange transfusion with liposome-encapsulated hemoglobin Circ. Shock. 37 1992 124 133
21. R. Rabinovici, A.S. Rudolph, F.S. Ligler, T.-L. Yue, and G. Feuerstein Liposome-encapsulated hemoglobin: an oxygen-carrying fluid Circ. Shock. 32 1990 1 17
22. R. Rabinovici, A.S. Rudolph, J. Vernick, and G. Feuerstein A new salutary resuscitative fluid: liposome encapsulated hemoglobin/hypertonic saline solution J. Trauma 35 1993 121 127
23. R. Rabinovici, A.S. Rudolph, J. Vernick, and G. Feuerstein Lyophilized liposome-encapsulated hemoglobin: evaluation of hemodynamic, biochemical, and hematologic responses Crit. Care Med. 22 1994 480 485
24. R. Rabinovici, A.S. Rudolph, T.-L. Yue, and G. Feuerstein Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist Circ. Shock. 31 1990 431 445
25. A.S. Rudolph, R. Cliff, V. Kwasiborski, L. Neville, F. Abdullah, and R. Rabinovici Liposome-encapsulated hemoglobin modulates lipopolysaccharide-induced tumor necrosis-alpha production in mice Crit. Care Med. 25 1997 460 468
26. A.S. Rudolph, T. Sulpizio, V. Kwasiborski, R.O. Cliff, R. Rabinovici, and G. Feurstein Infusion of liposome-encapsulated hemoglobin in normovolemic primates Artif. Cells Blood Substit. Immobil. Biotechnol. 24 1996 415
27. J. Szebeni, N.M. Wassef, H. Spielberg, A.S. Rudolph, and C.R. Alving Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation Biochem. Biophys. Res. Commun. 205 1994 255 263
28. J.M. van den Hoven, R. Nemes, J.M. Metselaar, B. Nuijen, J.H. Beijnen, G. Storm, and J. Szebeni Complement activation by PEGylated liposomes containing prednisolone Eur. J. Pharm. Sci. 49 2013 265 271
29. J. Szebeni, H. Spielberg, R.O. Cliff, N.M. Wassef, A.S. Rudolph, and C.R. Alving Complement activation and thromboxane A2 secretion in rats following administration of liposome-encapsulated hemoglobin: inhibition by soluble complement receptor type 1 Artif. Cells Blood Substit. Immobil. Biotechnol. 25 1997 379 392
30. Ambisome Package label www.ambisome.com 2009
31. V. Heinemann, D. Bosse, U. Jehn, B. Kähny, K. Wachholz, A. Debus, P. Scholz, H.J. Kolb, and W. Wilmanns Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients Antimicrob. Agents Chemother. 41 1997 1275 1280
32. F. Meunier, H.G. Prentice, and O. Ringdén Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial J. Antimicrob. Chemother. 28 Suppl. B 1991 83 91
33. R. Chopra, S. Blair, J. Strang, P. Cervi, K.G. Patterson, and A.H. Goldstone Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients J. Antimicrob. Chemother. 28 Suppl. B 1991 93 104
34. R.N. Davidson, L. Di Martino, L. Gradoni, R. Giacchino, R. Russo, G.B. Gaeta, R. Pempinello, S. Scott, F. Raimondi, and A. Cascio Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial Q. J. Med. 87 1994 75 81
35. J. Seaman, C. Boer, R. Wilkinson, J. de Jong, E. de Wilde, E. Sondorp, and R. Davidson Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions Clin. Infect. Dis. 21 1995 188 193
36. J. Tollemar, K. Hckerstedt, B.G. Ericzon, H. Jalanko, and O. Ringdén Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial Transplant. Proc. 27 1995 1195 1198
37. P. Schneider, R.M. Klein, L. Dietze, D. Sohngen, M. Leschke, and A. Heyll Anaphylactic reaction to liposomal amphotericin (AmBisome) Br. J. Haematol. 102 1998 1108
38. D. Schneberger, K. Aharonson-Raz, and B. Singh Pulmonary intravascular macrophages and lung health: what are we missing? Am. J. Physiol. Lung Cell. Mol. Physiol. 302 2012 L498 L503
39. J.G. Gaca, D. Palestrant, D.J. Lukes, M. Olausson, W. Parker, and R.D. Davis Jr. Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate J. Surg. Res. 112 2003 19 25
40. M.A. Sierra, L. Carrasco, J.C. Gomez-Villamandos, J. Martin de las Mulas, A. Mendez, and A. Jover Pulmonary intravascular macrophages in lungs of pigs inoculated with African swine fever virus of differing virulence J. Comp. Pathol. 102 1990 323 334
41. J. Szebeni, L. Baranyi, S. Savay, M. Bodo, J. Milosevits, C.R. Alving, and R. Bunger Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function Am. J. Physiol. Heart Circ. Physiol. 290 2006 H1050 H1058